NASDAQ:EOLS - Evolus Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.66 +0.35 (+2.84 %)
(As of 12/16/2018 12:21 PM ET)
Previous Close$12.66
Today's Range$12.1203 - $13.09
52-Week Range$6.75 - $39.50
Volume218,595 shs
Average Volume305,579 shs
Market Capitalization$345.30 million
P/E Ratio-46.89
Dividend YieldN/A
BetaN/A
Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
Previous Symbol
CUSIPN/A
Phone949-284-4555

Debt

Debt-to-Equity RatioN/A
Current Ratio19.43
Quick Ratio19.43

Price-To-Earnings

Trailing P/E Ratio-46.89
Forward P/E Ratio-6.88
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)($0.27)
Net Income$-4,480,000.00
Net MarginsN/A
Return on Equity-79.85%
Return on Assets-14.93%

Miscellaneous

Employees21
Outstanding Shares27,270,000
Market Cap$345.30 million
OptionableOptionable

Evolus (NASDAQ:EOLS) Frequently Asked Questions

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) posted its earnings results on Monday, November, 5th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by $0.09. View Evolus' Earnings History.

When is Evolus' next earnings date?

Evolus is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Evolus.

What price target have analysts set for EOLS?

4 brokers have issued 1 year price targets for Evolus' stock. Their predictions range from $27.00 to $35.00. On average, they anticipate Evolus' share price to reach $32.50 in the next year. This suggests a possible upside of 156.7% from the stock's current price. View Analyst Price Targets for Evolus.

What is the consensus analysts' recommendation for Evolus?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus.

What are Wall Street analysts saying about Evolus stock?

Here are some recent quotes from research analysts about Evolus stock:
  • 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (11/8/2018)
  • 2. Cantor Fitzgerald analysts commented, "Based on our due diligence, dermatologists and plastic surgeons appreciate the value proposition of Evolus’s botulinum toxin as a nearly identical product to market-leader Botox sold at a discount. Therefore, we think DWP-450 could pick up meaningful market share if it is approved. and other potential upcoming catalysts should drive EOLS shares higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $35 12-month price target." (9/17/2018)

Has Evolus been receiving favorable news coverage?

Media coverage about EOLS stock has trended positive on Sunday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolus earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the company's share price in the near future.

Who are some of Evolus' key competitors?

Who are Evolus' key executives?

Evolus' management team includes the folowing people:
  • Dr. Rui Avelar M.D., Chief Medical Officer & Head of R&D (Age 56)
  • Mr. David Moatazedi, Pres ,CEO & Director (Age 40)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 59)
  • Mr. Alejandro Sabad, VP of Operations
  • Jeffrey J. Plumer, VP of Legal

When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Who are Evolus' major shareholders?

Evolus' stock is owned by many different of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (2.78%), PointState Capital LP (2.42%), BlackRock Inc. (2.26%), Vanguard Group Inc. (1.49%), Vanguard Group Inc (1.49%) and Marshall Wace North America L.P. (0.89%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, Kristine Romine, Michael M Jafar and Vikram Malik. View Institutional Ownership Trends for Evolus.

Which institutional investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., PointState Capital LP, BlackRock Inc., Marshall Wace North America L.P., Vanguard Group Inc, Vanguard Group Inc., Luminus Management LLC and Tygh Capital Management Inc.. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, Kristine Romine, Michael M Jafar and Vikram Malik. View Insider Buying and Selling for Evolus.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $12.66.

How big of a company is Evolus?

Evolus has a market capitalization of $345.30 million. The company earns $-4,480,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Evolus employs 21 workers across the globe.

What is Evolus' official website?

The official website for Evolus is http://www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 17901 Von Karman Avenue Suite 150, Irvine CA, 92614. The company can be reached via phone at 949-284-4555 or via email at [email protected]


MarketBeat Community Rating for Evolus (NASDAQ EOLS)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  141 (Vote Outperform)
Underperform Votes:  118 (Vote Underperform)
Total Votes:  259
MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel